摘要
Chimeric antigen receptor T-cell (CAR-T) therapy has been approved for relapsed/refractory B-cell lymphomas and greatly improves disease outcomes. The impressive success has inspired the application of this approach to other types of tumors. The relapsed/refractory T-cell malignancies are characteristic of high heterogeneity and poor prognoses. The efficacy of current treatments for this group of diseases is limited. CAR-T therapy is a promising solution to ameliorate the current therapeutic situation. One of the major challenges is that normal T-cells typically share mutual antigens with malignant cells, which causes fratricide and serious T-cell aplasia. Moreover, T-cells collected for CAR transduction could be contaminated by malignant T-cells. The selection of suitable target antigens is of vital importance to mitigate fratricide and T-cell aplasia. Using nanobody-derived or naturally selected CAR-T is the latest method to overcome fratricide. Allogeneic CAR-T products and CAR-NK-cells are expected to avoid tumor contamination. Herein, we review the advances in promising target antigens, the current results of CAR-T therapy clinical trials in T-cell malignancies, the obstacles of CAR-T therapy in T-cell malignancies, and the solutions to these issues.
学科与关键词
- CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and ChallengesZhang, Xiaomin; Zhu, Lingling; Zhang, Hui; Chen, Shanshan; Xiao, Yang*Frontiers in Immunology, 2022, 13: 927153.被引 47
- CAR T-Cell Immunotherapy Treating T-ALL: Challenges and OpportunitiesRen, Anqi; Tong, Xiqin; Xu, Na; Zhang, Tongcun; Zhou, Fuling*; Zhu, Haichuan*Vaccines, 2023, 11(1): 165.被引 7
- Tumor buster-where will the CAR-T cell therapy 'missile' go?Qu, Chunrun; Zhang, Hao; Cao, Hui; Tang, Lanhua; Mo, Haoyang; Liu, Fangkun; Zhang, Liyang; Yi, Zhenjie; Long, Lifu; Yan, Luzhe; Wang, Zeyu; Zhang, Nan; Luo, Peng; Zhang, Jian; Liu, Zaoqu; Ye, Weijie; Liu, Zhixiong*; Cheng, Quan*Molecular Cancer, 2022, 21(1): 201.被引 24
